Governments have integrated incentives to accelerate and promote the approval of orphan drugs and the interest among pharmaceutical companies to develop these products is rising. However, expedited regulatory approval is by no means an assurance that orphan drugs will succeed in the marketplace.
Recent years have seen substantial progress in the search for cell and gene therapies, with new medicinal technologies presenting hope for tackling a wide range of diseases.1 Indeed, there are some experimental therapies currently in Phase II and Phase III that are hopeful for launch into the market within the next decade.2 There is tremendous opportunity […]
Pharmaceutical companies invest in pipeline assets that are scientifically attractive. In reality, only a fraction of assets in development make it to market. The success rate of asset developmental candidates from 2006 to 2015 was reportedly only 9.6%.1 At every phase of asset development, there is a risk of failing to proceed to the next […]